<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593694</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00030535</org_study_id>
    <nct_id>NCT03593694</nct_id>
  </id_info>
  <brief_title>Technology Delivered Diabetes-Modified Behavioral Activation Treatment</brief_title>
  <acronym>TECHDMBAT</acronym>
  <official_title>Technology Delivered Diabetes-Modified Behavioral Activation Treatment for AAs With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this proposal is to test the efficacy of a multi-component, high&#xD;
      intensity intervention, technology delivered, diabetes-modified behavioral activation&#xD;
      treatment (TECH DM-BAT) that incorporates: 1) diabetes education; 2) home telemonitoring; and&#xD;
      3) diabetes modified behavioral activation, delivered by nurses via smartphones is effective&#xD;
      in improving metabolic control in African Americans with poorly controlled type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes Mellitus is highly prevalent in the United States (CDC 2014) and African Americans&#xD;
      (AA) are disproportionately affected and have higher prevalence, poorer metabolic control and&#xD;
      greater risk for complications and death compared to White Americans. Evidence from the&#xD;
      literature show that effective interventions for AAs with Type 2 Diabetes Mellitus (T2DM)&#xD;
      have multiple components including: education and skills training, nurse case management, and&#xD;
      maintain high intensity. However, few large Randomized Clinical Trials (RCT) have tested&#xD;
      multi-component interventions that include these key components in AAs with T2DM.&#xD;
&#xD;
      Behavioral Activation is a psychotherapeutic process whereby patients are encouraged to&#xD;
      identify and schedule structured and enjoyable activities for behavior change that are likely&#xD;
      to improve outcomes such as mood, behaviors and quality of life. A brief manualized&#xD;
      behavioral activation treatment for depression (BATD), has been modified for diabetes.&#xD;
&#xD;
      This study tests a multi-component, high intensity intervention that incorporates several&#xD;
      strategies that have been shown to be effective in improving diabetes outcomes in AAs. Nurse&#xD;
      case managers will use videoconferencing technology to deliver education, skills training and&#xD;
      problem solving for diabetes via smartphones, an approach that has not been used previously&#xD;
      in vulnerable and underserved ethnic minority populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Service provider challenges precluded intervention delivery.&#xD;
  </why_stopped>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months</measure>
    <time_frame>baseline, 3-months, 6-months</time_frame>
    <description>Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled &quot;Your Guide to Sugar Diabetes&quot;. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled &quot;My Guide to Sugar Diabetes&quot;. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TECH DM-BAT</intervention_name>
    <description>Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TECH DMBAT Active Comparator</intervention_name>
    <description>Technology delivered diabetes education and home tele monitoring</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TECH DMBAT Other</intervention_name>
    <description>Technology delivered diabetes education</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥21 years&#xD;
&#xD;
          -  Clinical diagnosis of T2DM and HbA1c ≥8% at the screening visit;&#xD;
&#xD;
          -  Self-identified as AA&#xD;
&#xD;
          -  Subject must be willing to use the FORA monitoring system for 6 months&#xD;
&#xD;
          -  Subject must be willing to use the study assigned smartphone including&#xD;
             videoconferencing, lifestyle monitoring and medication monitoring apps for 6 months&#xD;
&#xD;
          -  Subjects must be able to communicate in English&#xD;
&#xD;
          -  Subjects must have access to a landline or Ethernet for FORA data uploads for the&#xD;
             study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mental confusion on interview suggesting significant dementia&#xD;
&#xD;
          -  Participation in other diabetes clinical trials&#xD;
&#xD;
          -  Alcohol or drug abuse/dependency&#xD;
&#xD;
          -  Active psychosis or acute mental disorder&#xD;
&#xD;
          -  Life expectancy &lt;6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard E Egede, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Egede, Leonard E</investigator_full_name>
    <investigator_title>Professor of Medicine, Chief Division of General Internal Medicine, Director Center for Patient Care and Outcomes Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

